Electromedical Technologies Business Summary

Electromedical Technologies, Inc. (EMED) is a commercial-stage bioelectronics firm that generates revenue through the manufacturing and sale of FDA-cleared electrotherapy devices designed for non-invasive pain management. The company operates across two primary segments: a professional healthcare channel serving clinics, chiropractors, and sports medicine specialists, and a direct-to-consumer e-commerce division that integrates HSA/FSA payment capabilities. Its flagship product line, including the WellnessPro Plus and the next-generation WellnessPro Infinity, utilizes proprietary DeepPulse ION technology to deliver customizable, multi-modality frequency treatments for chronic and acute conditions. EMED competes with bioelectronic and medical device companies such as Medtronic, NeuroMetrix, Curonix, and SetPoint Medical, positioning itself as a micro-cap innovator focused on drug-free alternatives to traditional pharmacotherapy and opioid treatments. The company was founded by Matthew Wolfson, who continues to lead as CEO, Chairman, and President, leveraging a background in technology and telecommunications as the former co-founder of Globalcom 2000. The executive team is bolstered by high-pedigree scientific and medical leadership, including Lead Scientific Advisor Dos D. Sarbassov, Ph.D., an expert in cell-signaling from the MD Anderson Cancer Center, and Chief Medical Advisor Alexander A. Pedenko, MD, a board-certified anesthesiologist. As of early 2026, the company is navigating a financial restructuring phase following a strategic 2025 agreement to retire major convertible notes and a voluntary suspension of SEC reporting to optimize internal resources. Notable strategic support has included a partnership with Lionheart Health, while the company continues to realign its board and advisory team to support the production scale-up of its Infinity platform.